Affordable Drugs for
important diseases
mission
The mission of TheracosBio is to provide access to new medications for patients with common diseases. The current approach to financing drug development in the U.S. presumes that a small fraction of eligible patients will be able to afford the latest medications, but for those patients, cost considerations will have little effect on utilization. Only after the drugs lose their patent exclusivity do they achieve widespread penetration in the target patient population. TheracosBio believes that appropriate pricing can meet its business needs while enabling improved access to the latest therapeutic technologies. The company is employing this strategy for the marketing of Brenzavvy® (bexagliflozin), a medication approved by the U.S. Food and Drug Administration in 2023.
leadership
Brenzavvy is approved by the U.S. Food and Drug Administration.
News and Events
October 17, 2024
TheracosBio and BAMCO Africa Partner to Bring Affordably Priced
Diabetes Medication to Sub-Saharan Africa
October 3, 2024
TheracosBio Partners with PBA Health to Provide Affordably Priced FDA-approved Diabetes Medication to Thousands of Independent Community Pharmacies
BRENZAVVY® reduces the costs of treating type 2 diabetes
August 27, 2024
Release of Negotiated Prices Under Inflation Reduction Act Reveals that BRENZAVVY® (bexagliflozin) Remains the Lowest Priced SGLT2 Inhibitor
BRENZAVVY® is Available Nationwide at $50 per Month or less through Leading Online and Independent Pharmacies.
April 15, 2024
Head-to-Head Study Finds BRENZAVVY® (bexagliflozin) Non-Inferior to
Dapagliflozin in Chinese Patients With Type 2 Diabetes
Research Adds to Evidence Showing BRENZAVVY’s Similarity to Other
SGLT2 Inhibitors.
February 14, 2024
TheracosBio Extends Partnership with Mark Cuban Cost Plus Drug Company
BRENZAVVY® (bexagliflozin) Is Now Available to Healthcare Businesses via Cost Plus Drugs Marketplace.
January 8, 2024
CV Safety Profile of TheracosBio’s BRENZAVVY® (bexagliflozin) Confirmed in Research Published in Diabetes, Obesity and Metabolism
Meta-Analysis Adds to Evidence that BRENZAVVY® (bexagliflozin) Offers a Critical, Cost-Effective Option for Patients with Type 2 Diabetes.
December 20, 2023
TheracosBio, IPC Announce Distribution Partnership to Make BRENZAVVY® (bexagliflozin) Available to Thousands of IPC Member Pharmacies
TheracosBio announced that BRENZAVVY® (bexagliflozin) will be available to Independent Pharmacy Cooperative (IPC) members. IPC is the nation’s largest group purchasing organization owned by independent pharmacy, serving more than 7,000 pharmacies and stocking more than 4,000 products. IPC will be the first pharmaceutical wholesaler to carry and distribute BRENZAVVY in the United States.
December 18, 2023
TheracosBio Announces Availability of BRENZAVVY® (bexagliflozin) Through DiRx’s National Online Pharmacy
BRENZAVVY will be priced at $47.75 a month and eliminates hassles associated with insurance benefit design.
August 22, 2023
TheracosBio Announces Royalty Financing Agreement with HealthCare Royalty
TheracosBio announced that its consolidated group of companies has signed a royalty financing agreement with HealthCare Royalty (HCRx).
August 17, 2023
TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Members with Type 2 Diabetes
TheracosBio and SmithRx today announced that SmithRx will offer access to BRENZAVVY™ (bexagliflozin), TheracosBio’s FDA-approved oral medication for adults with type 2 diabetes, through its partnership with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs).
August 4, 2023
TheracosBio Announces Publication of Data on the Safety and Effectiveness of Brenzavvy™ (bexagliflozin) as an Adjunct to Metformin
TheracosBio today announced the publication of a study titled “Bexagliflozin as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults: a 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial” in Diabetes, Obesity and Metabolism.
August 1, 2023
TheracosBio Appoints Brian Connelly as Chief Executive Officer
TheracosBio today announced the appointment of Brian Connelly as President and Chief Executive Officer.
July 13, 2023
TheracosBio Announces Commercial Availability of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
Distribution through Mark Cuban Cost Plus Drug Company introduces affordably-priced SGLT2 inhibitors.
March 13, 2023
TheracosBio Announces the Appointments of Jim Greenwood to Board of Directors and Jeff McGroarty as Chief Financial Officer
TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer.
January 23, 2023
TheracosBio Announces FDA Approval of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
Once-daily, oral SGLT2 inhibitor shown to reduce blood sugar and improve glycemic control as an adjunct to diet and exercise
Contact
TheracosBio, LLC
225 Cedar Hill Street, Suite 200
Marlborough, MA 01752
Please click [SUBMIT] only once.
A message will appear confirming the form has been sent successfully.